Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junping Zhang

Showing results (401-410 of 429) with videos related to

Pageof 43
Sort By:
British Journal of Haematology|March 11, 2022
The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm)Hui Wei, Chunlin Zhou, Bingcheng Liu, et al.
Circulation Research|January 26, 2024
Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac HypertrophyYingyu Bai, Xiaoying Zhang, Ying Li, et al.
JMIR Cancer|June 5, 2024
Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation StudyDi Zheng, Yanhong Shang, Jian Ni, et al.
The Lancet. Respiratory Medicine|June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trialZiming Li, Xiaomin Dang, Dingzhi Huang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2026
Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I StudyMinjiang Chen, Iurie Bulat, Marina Maglakelidze, et al.
Journal of Gastrointestinal Oncology|September 12, 2022
Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202)Xiang Wang, Diansheng Zhong, Junping Zhang, et al.
Nature Communications|June 12, 2023
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancerShen Zhao, Wu Zhuang, Baohui Han, et al.
Therapeutic Advances in Medical Oncology|March 29, 2020
An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)Xiang Wang, Ruixing Zhang, Nan Du, et al.
American Journal of Cancer Research|April 9, 2020
Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)Xiang Wang, Junyan Yu, Mudan Yang, et al.
Pageof 43

Showing results (401-410 of 429) with videos related to

Sort By:
Pageof 43
British Journal of Haematology|March 11, 2022
The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm)Hui Wei, Chunlin Zhou, Bingcheng Liu, et al.
Circulation Research|January 26, 2024
Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac HypertrophyYingyu Bai, Xiaoying Zhang, Ying Li, et al.
JMIR Cancer|June 5, 2024
Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation StudyDi Zheng, Yanhong Shang, Jian Ni, et al.
The Lancet. Respiratory Medicine|June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trialZiming Li, Xiaomin Dang, Dingzhi Huang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2026
Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I StudyMinjiang Chen, Iurie Bulat, Marina Maglakelidze, et al.
Journal of Gastrointestinal Oncology|September 12, 2022
Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202)Xiang Wang, Diansheng Zhong, Junping Zhang, et al.
Nature Communications|June 12, 2023
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancerShen Zhao, Wu Zhuang, Baohui Han, et al.
Therapeutic Advances in Medical Oncology|March 29, 2020
An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)Xiang Wang, Ruixing Zhang, Nan Du, et al.
American Journal of Cancer Research|April 9, 2020
Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)Xiang Wang, Junyan Yu, Mudan Yang, et al.
Pageof 43